These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 29754934)

  • 1. Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.
    Gao X; Jegede O; Gray C; Catalano PJ; Novak J; Kwiatkowski DJ; McKay RR; George DJ; Choueiri TK; McDermott DF; Signoretti S; Bhatt RS
    Clin Genitourin Cancer; 2018 Oct; 16(5):341-348. PubMed ID: 29754934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
    Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
    Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma.
    Alsidawi S; Kasi PM
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.
    Feldman DR; Ged Y; Lee CH; Knezevic A; Molina AM; Chen YB; Chaim J; Coskey DT; Murray S; Tickoo SK; Reuter VE; Patil S; Xiao H; Aghalar J; Apollo AJ; Carlo MI; Motzer RJ; Voss MH
    Cancer; 2020 Dec; 126(24):5247-5255. PubMed ID: 32975815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN Expression, Not Mutation Status in
    Voss MH; Chen D; Reising A; Marker M; Shi J; Xu J; Ostrovnaya I; Seshan VE; Redzematovic A; Chen YB; Patel P; Han X; Hsieh JJ; Hakimi AA; Motzer RJ
    Clin Cancer Res; 2019 Jan; 25(2):506-514. PubMed ID: 30327302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
    Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
    Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.
    Voss MH; Molina AM; Chen YB; Woo KM; Chaim JL; Coskey DT; Redzematovic A; Wang P; Lee W; Selcuklu SD; Lee CH; Berger MF; Tickoo SK; Reuter VE; Patil S; Hsieh JJ; Motzer RJ; Feldman DR
    J Clin Oncol; 2016 Nov; 34(32):3846-3853. PubMed ID: 27601542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
    Powles T; Lackner MR; Oudard S; Escudier B; Ralph C; Brown JE; Hawkins RE; Castellano D; Rini BI; Staehler MD; Ravaud A; Lin W; O'Keeffe B; Wang Y; Lu S; Spoerke JM; Huw LY; Byrtek M; Zhu R; Ware JA; Motzer RJ
    J Clin Oncol; 2016 May; 34(14):1660-8. PubMed ID: 26951309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.
    Jonasch E; Hasanov E; Corn PG; Moss T; Shaw KR; Stovall S; Marcott V; Gan B; Bird S; Wang X; Do KA; Altamirano PF; Zurita AJ; Doyle LA; Lara PN; Tannir NM
    Ann Oncol; 2017 Apr; 28(4):804-808. PubMed ID: 28049139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways.
    Son JY; Yoon S; Tae IH; Park YJ; De U; Jeon Y; Park YJ; Rhyu IJ; Lee BM; Chung KH; Lim JE; Lee SJ; Lee HW; Kwak JH; Kim HS; Choi HY
    Cancer Med; 2018 Oct; 7(10):5083-5095. PubMed ID: 30160042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines.
    Bodnar L; Stec R; Cierniak S; Synowiec A; Wcisło G; Jesiotr M; Koktysz R; Kozłowski W; Szczylik C
    Ann Oncol; 2015 Jul; 26(7):1385-9. PubMed ID: 25962440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
    Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
    Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
    Hamieh L; Choueiri TK; Ogórek B; Khabibullin D; Rosebrock D; Livitz D; Fay A; Pignon JC; McDermott DF; Agarwal N; Gao W; Signoretti S; Kwiatkowski DJ
    PLoS Genet; 2018 Sep; 14(9):e1007679. PubMed ID: 30256787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
    Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B
    BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.
    Oudard S; Joly F; Geoffrois L; Laguerre B; Houede N; Barthelemy P; Gross-Goupil M; Vano Y; Lucidarme O; Bidault F; Kelkouli N; Slimane K; Escudier B
    Clin Genitourin Cancer; 2016 Dec; 14(6):e595-e607. PubMed ID: 27283478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
    Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
    Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.
    Escudier B; Molinie V; Bracarda S; Maroto P; Szczylik C; Nathan P; Negrier S; Weiss C; Porta C; Grünwald V; Albiges L
    Eur J Cancer; 2016 Dec; 69():226-235. PubMed ID: 27680407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.
    Chen Z; Zheng Y; Cao W; Zhang Y; Zhao Z; Wang G; Zhao J; Cai S; Shao X; Huang J; Ye W; Huang Y; Li W; Huang X; Wu H; Wang X; Yin Y
    Cancer Med; 2019 Sep; 8(12):5544-5553. PubMed ID: 31385461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathogenesis and therapeutic options.
    Brown RE; Buryanek J; Tammisetti VS; McGuire MF; Csencsits-Smith K
    Oncotarget; 2016 Jul; 7(27):41612-41621. PubMed ID: 27223432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.
    Bono P; Oudard S; Bodrogi I; Hutson TE; Escudier B; Machiels JP; Thompson JA; Figlin RA; Ravaud A; Basaran M; Porta C; Bracarda S; Brechenmacher T; Lin C; Voi M; Grunwald V; Motzer RJ
    Clin Genitourin Cancer; 2016 Oct; 14(5):406-414. PubMed ID: 27287020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.